A study looking at a new drug, AZD5055, when combined with Nintedanib in healthy people

Upcoming study
Expected to open May 2023
This study is currently recruiting
Expected to close August 2023
This study is closed
This study closed in August 2023
We will update this page with study results when available.
Information on study results are included below
This study closed in August 2023
Ask your healthcare team about taking part in research

What next?

Unfortunately within research, studies can close earlier than planned if the results are not as expected.

This study finished early, as the researchers found that there were no connections between the drugs within the body. Although, the results may appear to be negative, outcomes such as this are just as important, as it lets us to know what doesn't work. Researchers can then focus on different potential new therapy options.

Original listing:

What next?

Unfortunately within research, studies can close earlier than planned if the results are not as expected.

This study finished early, as the researchers found that there were no connections between the drugs within the body. Although, the results may appear to be negative, outcomes such as this are just as important, as it lets us to know what doesn't work. Researchers can then focus on different potential new therapy options.

Original listing:

About this study

Nintedanib is an antifibrotic medication, which is approved as a treatment option for people with PF. It is a medicine that can help to slow down the rate of disease progression.

In this study researchers want to understand how the body responds when taking nintedanib with a new study drug, called AZD5055 in healthy people.

The aim is to understand if the new drug is affected by nintedanib.

 – 

What is involved?

This study is for healthy people. The study involves an initial time of 28 days where no treatment will be given, and then 3 different treatment periods at different time points. You will be given 2 treatments with nintedanib and the new drug at different doses, and then another treatment of just receiving nintedanib.

You will be asked to have blood tests and other clinical assessments throughout the study to understand the effects on the body.

Summary of involvement

Three different drug treatments during the study

Blood tests and other clinical assessments

Can I take part?

You may be able to take part if you are a healthy individual, aged 18 to 55 years.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the clinical trial team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Healthy non-smoker

Aged 18 to 55 years

Not of childbearing potential

Females must have a negative pregnancy test and must not be lactating

Male participants and their women partners must be willing to use highly effective contraception measures.

You will not be able to join the study of any of the following applies:

History or presence of clinically significant disease

History of significant illness, medical/surgical procedure or trauma within the last 4 weeks

Untreated tuberculosis

Individuals with chronic infections or those at risk of infection

History of severe COVID-19 infection requiring hospitalisation within the last 12 months

Has received a live or live attenuated vaccine within the last 30 days

History of severe allergies

Use of any prescribed or non prescribed medication

People who have previously received the study drug

What difference could taking part make?

Taking part in this study will help researchers to understand the effect of the new drug and the body's response when also taking nintedanib. This study is initially in healthy individuals, with the aspiration to find more effective treatments for people with PF.

Where does the study take place?

Study locations

Glendale

How to take part

Further information

The summary on this page provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.

information.center@astrazeneca.com

This study is supported by

AstraZeneca
Parexel
Study ID number:
NCT05644600

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org